Skip to main content
OpenTrials
Completed

NCT Number: NCT04062396

Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction

Age is no longer an absolute contraindication to cardiac surgery therefore there is often need for combined interventions (double valve repair/replacement, or coronary artery bypass graft and valve repair/replacement) with relative prolongation of cardiopulmonary bypass time. Prolonged cardiopulmonary bypass use causes an increase in the inflammatory response, and on the other a need for blood reinfusion and therefore lipid microemboli from the operative field. The clinical consequences for patients are post-operative delirium and post-operative cognitive impairment.

These two neurological complications involve up to 45% of elderly patients undergoing cardiac surgery and have a significant impact on quality of life, hospitalization and mortality in the short and long term. The Remowell 2 oxygenator system has demonstrated in preliminary studies that, compared to the gold standard Inspire oxygenator, it can guarantee a significant reduction of hemodilution, inflammatory systemic response and embolization of lipid microemboli and leukocytes. In light of these considerations, it is possible to formulate the hypothesis that the use of the Remowell 2 device can contribute to significantly reducing the onset of post-operative delirium and cognitive impairment. The present study is designed to validate this hypothesis in a randomized controlled scenario.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Maria Cecilia Hospital

Cotignola, Ravenna, 48010, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signature of informed consent for participation in the study
  • Age ≥65 years
  • Patients undergoing cardiac surgery of:
  • coronary artery bypass graft and concomitant valve replacement/repair OR
  • double valve replacement/repair

Exclusion criteria

  • Any documented history of cognitive impairment estimated as a mini mental state examination < 24 points
  • Patients who need blood prime in the cardiopulmonary bypass circuit
  • Chronic coagulopathies ( international normalized ratio > 2 in patients without anticoagulant treatment)
  • End stage renal disease on dialysis treatment
  • Previous cerebrovascular accident
  • Active cancer or immunological diseases
  • Liver cirrhosis (platelets <100.000/uL)
  • Decompensated diabetes
  • Severe preoperative anemia (hemoglobin <8 g/dl).

Treatment and study plan

Eurosets REMOWELL 2 oxygenator

Device

The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion

LivaNova INSPIRE oxygenator

Device

INSPIRE oxygenator has no filtration system for extracavitary inlet

Primary outcomes

  1. post-operative delirium

    Time frame: 6 days

    In-hospital incidence of post-operative delirium assessed by Confusion Assessment Method (CAM) diagnostic algorithm

Sponsors and collaborators

Lead sponsor

Maria Cecilia Hospital

Other

Registry information

Official study title

Randomized Comparison Between Oxygenator Systems for the Reduction of Post-operative Delirium in Older Patients Undergoing Cardiac Surgery

Acronym: CRIDD

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Aug 20, 2019
Registry last updated
Feb 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.